The French Embassy was the setting for the official presentation of Efluelda, the innovative flu vaccine developed by Sanofi.
Céline Giusti, First Counselor of the embassy, welcomed the event which was attended by Pharmabiz. Serge Montero, general manager of Sanofi Vaccines for the Southern Cone, highlighted Sanofi's vast experience in vaccine research and production, with more than 120 years in the field and a wide range of vaccines that protect against more than 15 infectious diseases.
During the meeting titled "Innovating the future of flu vaccines", cardiologist Jorge Tartaglione spoke about the silent impact of influenza, while Pablo Bonvehí, head of Infectology at CEMIC, addressed the high-dose vaccine as an alternative for enhanced protection for adults.
Natalia Espinola, coordinator of Health Economics at IECS, presented aspects of pharmacoeconomics. The event included a question and answer session moderated by Rocío Bassons, director of Vaccine Marketing, and featured the participation of Florencia Esquivel, Medical Director of Vaccines for the Southern Cone.
Attendees, from various health sectors, included opinion leaders, representatives of scientific societies, key players in the health system, academics, as well as representatives of vaccination centers, pharmacies and drug wholesalers.
Efluelda, the new vaccine, stood out for being the first and only high-dose tetravalent flu vaccine, aimed at adults over 65 years old.
With four times more antigens than the standard vaccine, it joins Sanofi's portfolio of flu vaccines, which includes Istivac 4 for universal protection from 6 months of age.
Both vaccines will be available in Argentina in the upcoming season, contributing to protection against influenza and its complications, such as pneumonia, myocardial infarction and strokes.
With information from: Pharmabiz.net
Receive all industry news in our weekly newsletter Dialéctica Científica.